$CLVT

CLARIVATE PLC

Clarivate provides intelligence solutions, workflow software and technology-enabled services to customers in academia and government, intellectual property, and life sciences and healthcare. Its customers include academic institutions and libraries, research organizations, corporations, law firms, government entities, and pharmaceutical, biotechnology, and medical device companies. Clarivate is headquartered in London, United Kingdom. Clarivate operates through three segments. Academia & Government offers research and learning products and services, including Web of Science, ProQuest, Alma, Vega and Polaris. Intellectual Property provides patent and trademark services, data and software, including Derwent, CompuMark, IPfolio and FoundationIP. Life Sciences & Healthcare offers research and development, commercial and medtech intelligence, including the Cortellis product suite. Clarivate earns money primarily through subscriptions and recurring contracts, including patent and trademark renewal services, as well as transactional sales of content, consulting and professional services.

AlphAI earnings readThird Quarter 2026 · NOV 3Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value CreationVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
0
—
$542K
Veinstein Bar
100%
See all $CLVT insider activity →
Low

Veinstein Bar sold $542K of CLVT

Veinstein Bar (President, A&G) sold 254,558 shares of CLARIVATE PLC (CLVT) at $2.13 ($0.54M total) on 2026-11-18 under a Rule 10b5-1 trading plan.

CLVT: AI-led product growth and debt reduction anchor the next phase

Clarivate Plc (CLVT) reported a shift to AI-led, subscription-based products, aiming for 10%-15% FY 2027 free cash flow growth and debt reduction. Management targets margin maintenance while driving retention and new business growth, according to a conference transcript.

Clarivate (CLVT) Adds Patent And Litigation Data To Claude

Clarivate (CLVT) integrated Derwent patent and Darts-ip litigation data into Claude via IPOne, adding to existing CompuMark trademark data. The move expands IP intelligence distribution, but no financial details or impact were disclosed.

CLVT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLVT (CLARIVATE PLC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent CLVT coverage spans earnings, financial news and corporate actions.

In the last 30 days, CLVT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($542K). The most active reporter was Veinstein Bar, President, A&G, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving CLVT

AlphAI scores every news story that mentions CLVT with an AI model for sentiment and relevance, and aggregates insider trades from CLARIVATE PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CLVT

Score

Clarivate Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

Clarivate Plc (CLVT) announced pricing terms for its cash tender offers to purchase certain outstanding debt securities. The company is offering to buy back its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, with a total consideration of $979.08 and $928.75 per $1,000 principal amount, respectively. The offers are subject to a $500 million cap and other conditions.

Jefferies raises Clarivate stock price target on ACV improvement

Jefferies raised its price target on Clarivate (NYSE:CLVT) to $2.25, citing improved annual contract value but noting slower organic revenue growth. The company reported Q3 2026 earnings, beating EPS estimates but missing revenue targets. Clarivate maintains a 68% gross profit margin and expects continued ACV growth. Stifel reiterated a Buy rating with a $5.00 target, citing strong IP unit performance and AI-driven business growth.

Clarivate stock gains on positive growth outlook from Stifel

Stifel reiterated a Buy rating and $5.00 price target for Clarivate (NYSE:CLVT) after its IP unit showed 1% organic growth and positive ACV growth. Clarivate expects 2% organic growth in Q4 2026 and 9-18% free cash flow growth in 2027. The stock rose 24% intraday. Q3 2026 earnings beat estimates at $0.21 per share, but revenue missed at $481.6M.

What Clarivate (CLVT) Said on Its Q3 Earnings Call

Clarivate (CLVT) reported Q3 earnings, highlighting 1% growth in recurring organic revenue and positive ACV growth. The company cited a U.S. Patent and Trademark Office selection and plans for an AI-native IP platform, IPOne. Margins expanded by 300 basis points, and the company updated its 2026 outlook, excluding divested businesses. CLVT expects $1.965B-$1.985B in revenue and $865M-$885M in adjusted EBITDA.

Related tickers